There is research on this stock available only to PRO subscribers.
Yesterday, 6:36 PM
- Akorn (AKRX -3.8%) acquires the rights to the short-acting bronchodilator Xopenex (levalbuterol HCI) Inhalation Solution from Sunovion Pharmaceuticals for $45M in cash, net of certain liabilities.
- The transaction will add $18M - 20M to Akorn's top line and $0.07 - 0.08 to EPS in 2015 excluding the impact of acquisition-related amortization.
- Per IMS Health, the U.S. market for the branded and generic versions of Xopenex is ~$280M.
Thu, Sep. 11, 4:07 PM
- Akorn (AKRX +3.4%) is supposedly exploring a bid for the U.S. subsidiary of Belgian drugmaker UCB SA, generics firm Kremers Urban Pharmaceuticals, for as much as $2B.
- The transaction would enable it to move its tax domicile overseas.
- According to accounting firm PricewaterhouseCoopers, Akorn's current effective tax rate of ~37% is significantly higher than the industry average of ~23%.
Tue, Aug. 5, 8:47 AM
- Akorn (NASDAQ:AKRX) preliminary Q2 results: Revenues: $150.7M (+95.7%); Gross Profit: $76.7M (+82.2%); Operating Expenses: $60.4M (+205.1%); Operating Income: $16.3M (-26.9%); Net Income: $8.5M (-32.5%); EPS: $0.07 (-36.4%); Quick Assets: $107.9M (+215.5%); Cash Burn: ($3.6M) (-124.8%).
- 2014 Guidance: Revenues: $580M - 600M; GAAP net income: $63M - 69M; GAAP EPS: $0.53 - 0.58; non-GAAP net income: $118 - 125M; non-GAAP EPS: $1.00 - 1.05; CAPEX: $35 - 40M.
Tue, Aug. 5, 6:05 AM
Tue, Aug. 5, 1:53 AM
- The Federal Trade Commission has given U.S. antitrust approval to Akorn's (NASDAQ:AKRX) acquisition of prescription drug-maker VersaPharm on condition that Akorn sell its rights to make a generic version of the tuberculosis drug rifampin.
- Akorn entered into a definitive agreement in May to purchase VersaPharm for $440M.
- Watson Laboratories, a subsidiary of Actavis (NYSE:ACT), has agreed to buy Akorn's rights to rifampin.
- ACT +1.5% AH
Mon, Aug. 4, 5:30 PM
- ACM, ACT, ADM, AEE, AKRX, ALLT, AME, AMSC, ANSS, ARCC, ARCO, ARQL, BCRX, BLMN, CIE, CLDT, CNK, COH, CRZO, CVC, CVS, DWRE, EMR, END, ENZY, EXH, EXLP, EXPD, FE, FUN, GLDD, GTIV, GTXI, HCLP, HCP, HEP, IART, IFF, IIVI, INFI, IT, KWK, LIN, LPX, MDU, MGM, MMP, MSI, MWW, MZOR, NILE, NNN, [[NTi]], NVDQ, NWN, ODP, OXF, OZM, PMC, RBA, REGN, RHP, RIGL, RTI, SCMP, SCOR, SMG, SNSS, SPAR, STE, TDG, VMC, VSI, VTG, WLK, WNR, ZBRA, ZTS
Fri, Jun. 20, 12:06 PM
- Citing a poor strategic fit with its focus on niche dosage forms, Akorn (AKRX +3.3%) sells its subsidiary ECR Pharmaceuticals to Valeant Pharmaceuticals (VRX +2.9%) for $41M in cash and the assumption of certain liabilities. Akorn acquired the branded drug maker when it purchased Hi-Tech Pharmacal last year.
Fri, May. 9, 11:10 AM
- Akorn (AKRX +3.8%) enters into a definitive agreement to acquire VPI Holdings, the parent company of VersaPharm for $440M cash.
- VersaPharm is a privately-held maker of multi-source prescription drugs focused on niche applications in dermatology, TB and hemophilia. It has a pipeline of over 20 products and 11 ANDAs under regulatory review.
- The acquisition is expected to add $90M - 100M in revenues and $0.10 - 0.12 in EPS, excluding certain items. Akorn will fund the purchase with debt.
Tue, May. 6, 10:07 AM
- Akorn (AKRX -0.7%) revenues: $90.6M (+22.6%); operating income: $23.4M (+25.8%); net income: $9.8M (-9.3%); EPS: $0.08 (-20.0%); cash and equiv at quarter end: $45.6M (+33.3%); CF Ops: $23.4M (+239%).
- 2014 guidance: total revenues: $540M - 560M; gross margin: 52 - 54%; net income: $51M - 53M, CAPEX: $45M - 55M.
Tue, May. 6, 7:02 AM
Mon, May. 5, 5:30 PM
- ACM, ACOR, AER, AKRX, AME, ARCC, ARCO, ARW, BCE, BCS, CBOE, CNK, COCO, CRTO, CRZO, CYNO, DISCA, DNR, DTV, DWRE, EMR, EXH, EXLP, FE, GDP, GLDD, HCP, HFC, HPT, HSH, HSIC, HTH, IFF, ISIS, KWK, MMP, MNTA, MONT, MOS, MPW, MSO, MVIS, MWIV, NRG, [[NTi]], NUS, ODP, OXF, PDCE, PQ, PRIM, RDC, RHP, RTI, RTRX, STWD, TDG, TGH, TPH, TW, UBS, VMC, VSH, VTG, WCG, WNR, XRAY, ZBRA, ZTS.
Thu, Apr. 17, 4:44 PM
- Actavis (ACT) buys four currently-marketed products from Akorn (AKRX) and one more under development for cash. The transaction is contingent on the consummation of Akorn's acquisition of Hi-Tech Pharmacal (HITK).
- The products on the market are: Ciprofloxacin Hydrochloride Ophthalmic Solution, Levofloxacin Ophthalmic Solution, Lidocaine Hydrochloride Jelly and Lidocaine/Prilocaine Topical Cream.
- The FTC stipulated that Akorn divest the products as a condition of its approval of the Hi-Tech transaction.
- Financial terms are not disclosed.
Tue, Apr. 15, 2:16 PM
Mon, Mar. 3, 10:21 AM| Comment!
Mon, Mar. 3, 6:01 AM
Mon, Mar. 3, 12:05 AM
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.
AKRX vs. ETF Alternatives
Other News & PR